Global Opioid Induced Constipation Treatment Market: Snapshot
There are multiple drugs in the pipeline for opioid induced constipation treatment. Upon approval, these drugs will face little competition in this market which is largely untapped. There have not been many stable choices in the pharmaceutical industry for opioid induced constipation treatment over the recent past, but the continuous approval rate of highly targeted drugs is expected to provide a strong push to this market’s growth rate. This includes the PAMORA drugs that help treat OIC without intervening in the opioid’s action on the patient.
The opioid induced constipation treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on the dosage form of the drug, type of drug class, and their geographical analysis. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises regulatory framework for major countries and event impact analysis. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global opioid induced constipation treatment market.
Mu-opioid Receptor Antagonists to Overtake Chloride Channel Activators by 2023
Till the end of 2016, chloride channel activators are expected to be the more popular drug class of opioid induced constipation treatments. This trend will continue for the coming years, but in time it is predicted that mu-opioid receptor antagonists will take the leading role among drug classes. A key reason for the popularity of chloride channel activators is the high level of sales of Amitiza ever since it was approved in 2013 and used specifically for opioid induced constipation treatment.
Over time, the growing number of mu-opioid receptor antagonists being approved and their greater efficacy over other drug classes is expected to push it to the top of the charts in terms of revenue generation before 2023. This drug class will also benefit from the increasing number of prescriptions being filed for opioid induced constipation treatments due to developments that reduce their side effects.
The leading providers of opioid induced constipation treatment include AstraZeneca, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant, Bayer, C.B. Fleet Company, Inc., Boehringer Ingelheim, Daewoong Co. Ltd., and Cosmo Pharmaceuticals.
Browse the full Opioid Induced Constipation Treatment Market: (Mu-opioid Receptor Antagonist, Chloride Channel Activator, and Others; Solid, Semi-solid, and Liquid): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023 report at http://www.transparencymarketresearch.com/opioidinduced-constipation-treatment-market.html
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453